Posting Date: December 16, 2020

Closing Date: December 26, 2020 5:00 p.m. ET

Reference Number: 21-011756

To: NCI Bid Board

From: Tanya Alfred
NCI CCR P-ARC
Tanya.alfred@nih.gov

Subject: NCI Bid Board Posting – Service Agreement

The Laboratory of Genitourinary Cancer Pathogenesis (LGCP) focuses on genitourinary (GU) cancers, especially prostate cancer, with the goal of understanding fundamental processes of cancer pathogenesis and translating this knowledge into clinical applications. LGCP work within the Urologic Oncology Collaborative Group, which brings together integrated basic and translational research, surgical oncology, and medical oncology for the purpose of improving the detection, diagnosis, and treatment of patients with GU cancers. Specifically, LGCP includes mechanism-oriented research programs to investigate the action of common prostate cancer genomic mutations, microenvironmental influences on tumor progression and metastasis development, castration resistance and prostate cancer stem cells, and the regulation of responses to cell death pathways.

The LGCP seeks to procure a Service Agreements for AB Assurance plan for Arcturus Laser Capture Microdissection System.

The National Cancer Institute plans to purchase a Service Agreement for AB Assurance plan for Arcturus Laser Capture Microdissection System from Life Technologies. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 5:00 PM on December 26, 2020 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

The Laboratory of Genitourinary Cancer Pathogenesis has an Arcturus Laser Capture Microdissection (LCM) System. Due to complexity of the instrument (which employs a dual laser system, an UV laser and an IR laser used in conjunction, precisely calibrated and tracked by the software to capture tissues samples for downstream analysis) and the fact that the instrument is used by multiple researchers from the LGCP in the NCI to process numerous amounts of precious patient prostate tissue samples for analysis, minimal downtime of the equipment is essential. Life Technologies manufactures the replacement parts needed for repairs. Life Technologies also uses trained personnel to perform all repairs, to ensure the proper calibration of the microscope system to ensure accurate laser performance. Life Technologies is the only company that can provide the services needed to keep the Arcturus LCM system at the optimum functionality.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request